Physician profile
Timothy E Daum
NPI 1700832615
$2,119.70
in general payments reported to CMS, 2019-2025
15 companies · $398 in 2025
The $398 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $52.73 · 2021: $114 · 2022: $441 · 2023: $620 · 2024: $196 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $880.74 | 2022-2025 | Inspire |
| Zoll Respicardia, INC. | $436.79 | 2019-2023 | Remede System |
| Intuitive Surgical, INC. | $233.32 | 2022 | |
| Jazz Pharmaceuticals INC. | $156.68 | 2019-2025 | Xywav |
| Harmony Biosciences LLC | $139.38 | 2021-2023 | Wakix |
| Grifols USA, LLC | $55.44 | 2024-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $47.40 | 2023-2024 | Sunosi |
| Noctrix Health, INC. | $40.43 | 2024 | Nidra |
| Eisai INC. | $24.75 | 2021 | |
| 3b Medical, INC. | $23.48 | 2025 | Luna |
| Avadel Cns Pharmaceuticals, LLC | $21.15 | 2024 | Lumryz |
| Lilly USA, LLC | $16.58 | 2025 | Zepbound |
| Resmed Corp | $15.80 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.83 | 2025 | Tezspire |
| Sunovion Pharmaceuticals INC. | $12.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Daum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.